GlobeNewswire

VITEC to Present Latest Innovations in HEVC Video Encoding/Decoding and IPTV and Digital Signage Platform at CCBN in Beijing

Dela

PARIS, March 07, 2018 (GLOBE NEWSWIRE) -- VITEC, a worldwide leader in advanced video encoding and streaming solutions, will demonstrate its video encoding, streaming, and media asset management (MAM) solutions at the China Content Broadcasting Network (CCBN) exhibition, March 22-24 at the China International Exhibition Center in Beijing. In Hall 2, Stand 2108, VITEC will highlight the company's point-to-point HEVC/H.264 streaming solutions for satellite, public internet and wireless transmission, as well as the company's EZ TV broadcast-grade IPTV and digital signage platform, delivering live and on-demand video in concert with the PX Media Library MAM solution.

On display at CCBN will be VITEC's point-to-point/point-to-multipoint HEVC streaming offering, featuring the award-winning MGW Ace hardware-based HEVC encode/decode solution. Using VITEC's second-generation 4:2:2 10-bit HEVC codec (Gen2), the compact, powerful streaming solution provides unmatched video quality and efficient bandwidth compression. Advanced, built-in stream protection guarantees reliable video distribution over any network, including the internet. In addition, MGW Ace can reduce the streaming latency down to 70ms end-to-end.

Also at CCBN, VITEC will demonstrate new advancements for EZ TV, the company's industry-leading IPTV and digital signage platform. With easy-to-use tools for signage authoring, administration, and analytics EZ TV automates video streaming workflows and signage campaigns over existing IP networks, allowing any organization to centrally manage IPTV and signage content from a single interface. A truly future-proof platform, EZ TV supports both H.264 and H.265 (HEVC) formats in resolutions up to 4K, combined with AES encryption to ensure secure content delivery. The solution's hardware-based IPTV and signage endpoints feature low-latency playback, real-time updating of the electronic program guide, video-on-demand content with updating of new assets in real time, time-shifted TV, live video access via PC and mobile, and user-controlled mosaic viewing of multiple channels.

VITEC will also showcase its PX Media Library, a timesaving meta-solution that enables media professionals to seamlessly tag, edit, manage, organize, and share media files. PX Media Library streamlines media management and allows users to take advantage of proven solutions for broadcast, sports, content distribution, government applications, and more. This open system is easily adaptable to industry-specific workflows and includes an intuitive user interface along with customizable, easy-to-configure workflows that keep users ahead of the competition by enabling them to stay organized in today's media-crowded world. PX Media Library integrates seamlessly with VITEC's powerful EZ TV IPTV and digital signage platform.

More information on VITEC's full line of products is available at www.vitec.com.

About VITEC
VITEC is a leading worldwide end-to-end video streaming solutions provider for broadcast, military and government, enterprise, sports and entertainment venues, and houses of worship. © 2018 VITEC

PR Link:  www.ingearpr.com/VITEC/180307VITEC.docx

Image Link:  http://www.ingearpr.com/VITEC/VITEC_MGW-ACE-Pair.jpg
Caption: VITEC MGW Ace Encoder and MGW Ace Decoder

Media Contact:
Peggy Blaze
InGear 
Tel: +1 (818) 357-3693
Email: peggy@ingearpr.com
 

 

Social Media Links: 
LinkedIn: https://www.linkedin.com/company/vitec-multimedia  
Twitter: https://twitter.com/Vitec_MM   
YouTube: http://www.youtube.com/user/vitecmm




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VITEC via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum